Canada’s clinical trial regulatory framework is in the middle of its most significant overhaul since Part C, Division 5 of the Food and Drug Regulations came into force in 2001. Two parallel tracks are moving at once: a proposed rewrite of the regulations that govern how drug trials are authorized and conducted in Canada, and Health Canada’s adoption of the revised international Good Clinical Practice guideline, ICH E6(R3). This post summarizes what has actually happened, what is still only proposed, and the current timeline as of this writing.
The draft Clinical Trials Regulations: what changed on December 20, 2025
On December 20, 2025, Health Canada pre-published proposed Clinical Trials Regulations in the Canada Gazette, Part I (Vol. 159, No. 51), opening a formal public comment period as part of its Clinical Trials Regulatory Modernization Initiative. The proposed regulations would replace the current framework for drug trials involving human subjects — Part C, Division 5 of the Food and Drug Regulations, in force since September 1, 2001, plus Part 2 of the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations — with a single, purpose-built regulatory chapter for drug clinical trials.
The stated policy goal is a shift from a largely prescriptive, one-size-fits-all authorization model toward flexible, risk-based oversight applied across a trial’s full lifecycle, not just at the initial Clinical Trial Application (CTA) stage. Legal commentary tracking the proposal (Norton Rose Fulbright, Torys, and Smart & Biggar among the firms that published early analyses) describes the intent as reducing regulatory burden for lower-risk trials while preserving — and in places tightening — oversight where risk to participants is higher.
Alongside the draft regulations, Health Canada released draft guidance on decentralized clinical trials on December 23, 2025, with its own consultation period. The decentralized-trial guidance previews flexibilities the eventual regulations are expected to formalize, including allowing informed consent to be obtained orally or via electronic signature in defined circumstances, and expanding the categories of health professionals who may act as trial investigators — both aimed at trials that use remote visits, local labs, or direct-to-participant investigational product shipment rather than a single physical trial site.
Comment period, extension, and what happens next
The original 90-day comment window on the draft regulations and related guidance was set to close March 20, 2026. Multiple law-firm trackers subsequently reported that Health Canada extended the consultation to April 19, 2026 (a roughly 120-day window from pre-publication), giving sponsors, contract research organizations, research ethics boards, and academic health centers more time to respond to a proposal that touches nearly every stage of trial conduct in Canada.
Per Health Canada’s own published process for this initiative, the next step is an interim “What We Heard” report summarizing themes from the comments received, which Health Canada will weigh in finalizing the regulatory text. Reporting from firms tracking the file places final publication in Canada Gazette, Part II around spring 2027, with the regulations themselves anticipated to come into force in spring 2028. Those are current projections, not committed dates — Canada Gazette Part II timelines routinely shift, and nothing about the spring 2027/2028 estimates should be treated as final until Health Canada publishes them. As of this writing, the regulations remain a draft; no comment received a final answer, and no consolidated final text is yet public. Organizations should treat the current Part C, Division 5 framework, covered in CASRAI’s guide to Canada’s clinical trial regulatory framework, as the operative rules today, while tracking this proposal as a multi-year transition already in motion.
ICH E6(R3): a separate, faster-moving track
Running alongside the regulations rewrite, but legally distinct from it, is Health Canada’s adoption of ICH E6(R3), the revised core Good Clinical Practice guideline from the International Council for Harmonisation. ICH finalized E6(R3) at Step 4 on January 6, 2025. Health Canada announced full adoption of E6(R3), effective April 1, 2026, replacing the prior ICH E6(R2) (2016 addendum) as the GCP standard Health Canada expects trial sponsors, investigators, and research ethics boards to follow. Health Canada is providing a roughly six-month preparatory period from that adoption date — commentary tracking the transition (including analysis from clinical-research consultancy MFLRC) points to an effective compliance deadline around October 1, 2026, intended to give sponsors, sites, and CROs time to retrain staff, revise standard operating procedures, and update quality management systems before E6(R3) is the guideline actually applied in inspections and reviews.
E6(R3) itself is a substantive revision, not a light edit: it restructures the guideline around Principles, a core integrated addendum, and annexes (Annex 1 for interventional trials, Annex 2 for trials incorporating decentralized, pragmatic, or real-world-data elements), and it elevates quality-by-design and proportionate, risk-based oversight to organizing principles of the guideline itself rather than treating them as an add-on, which is the same direction of travel as the draft Clinical Trials Regulations described above. The two tracks are not the same instrument — E6(R3) is guidance Health Canada has adopted by reference, not a regulation Health Canada itself writes and enforces through the Gazette process — but they are moving in a coordinated direction: both push Canadian trial oversight toward risk-proportionate, technology-enabled conduct rather than uniform, checklist-style requirements applied identically to every trial regardless of risk.
What this means for sponsors and institutions operating in Canada right now
- The current CTA process has not changed. Phase I–III drug trials in Canada still require a Health Canada No Objection Letter under the existing Part C, Division 5 process, described in CASRAI’s guide to Canada’s Clinical Trial Regulatory Framework, alongside Research Ethics Board approval. Nothing in the draft regulations is in force yet.
- ICH E6(R3) readiness is the nearer-term action item. With an April 1, 2026 adoption date already passed and a preparatory period expected to run to around October 1, 2026, organizations conducting or overseeing Health Canada-regulated trials have a materially shorter runway to align SOPs, training, and quality management systems with E6(R3) than they do for the draft regulations, which remain years from taking effect.
- The draft regulations are still open to influence, but the window narrows fast. With the comment period closed as of April 19, 2026, direct public input on the current draft text has passed; the live opportunity now is tracking the “What We Heard” report and any subsequent consultation Health Canada opens as it moves toward Gazette Part II.
- Research offices and REBs should expect convergence, not replacement, of frameworks. The direction of both tracks — risk-based, lifecycle oversight rather than static, upfront-only review — mirrors the same shift already visible in TCPS2 and in comparable modernization efforts at other regulators; institutions that have already built risk-tiered monitoring and REB review processes are better positioned for both changes than those relying on a single fixed CTA-stage review.
Frequently asked questions
Is the draft Clinical Trials Regulations already in force in Canada?
No. As of this writing it remains a proposal, pre-published in Canada Gazette, Part I on December 20, 2025, with its comment period closed April 19, 2026. Final text is expected in Canada Gazette, Part II, with current tracking pointing to spring 2027 for publication and spring 2028 for the regulations coming into force — both are current projections, not confirmed dates.
Is ICH E6(R3) already in force in Canada?
Health Canada announced adoption effective April 1, 2026, with a roughly six-month preparatory period reported to run to around October 1, 2026 before it is applied as the operative GCP standard in inspections and reviews. Sponsors and sites should not wait for the draft regulations to align their GCP practices with E6(R3) — the two tracks are on very different timelines.
Do the draft regulations cover medical devices and natural health products too?
The proposed Clinical Trials Regulations, as pre-published, establish a new framework specifically for clinical trials of drugs for human use, replacing Part C, Division 5 of the Food and Drug Regulations and Part 2 of the Clinical Trials for Medical Devices and Drugs Relating to COVID-19 Regulations. Reporting reviewed for this post did not identify a parallel, simultaneously-published overhaul of the separate medical device clinical trial framework; organizations working across product types should confirm current scope directly against Health Canada’s consultation materials rather than assume drug-trial changes carry over automatically.
What should a research office do today?
Treat ICH E6(R3) alignment (SOPs, training, quality management systems) as the near-term priority given its shorter runway, while assigning someone to monitor Health Canada’s “What We Heard” report and subsequent Clinical Trials Regulatory Modernization Initiative updates so the eventual final regulations don’t arrive as a surprise.
This is a fast-moving file with a multi-year timeline. CASRAI will update related pages as Health Canada publishes its “What We Heard” report and moves toward Canada Gazette, Part II; treat specific future dates in this post (spring 2027, spring 2028, October 2026) as current projections reported by outside trackers rather than dates Health Canada has itself finalized.
